Two medicines, side by side
Sitagliptin vs dapagliflozin
Sitagliptin and dapagliflozin are both labeled for type 2 diabetes. Drugs@FDA records approvals of sitagliptin since 2006 and of dapagliflozin since 2014. Pharmacies paid $3.77 per sitagliptin phosphate 100 mg tablet and $0.184 per dapagliflozin 10 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, sitagliptin is a dipeptidyl peptidase 4 inhibitor and dapagliflozin a sodium-glucose cotransporter 2 inhibitor.
Check it at the source: the sitagliptin FDA label on DailyMed (effective November 14, 2024); the dapagliflozin FDA label on DailyMed (effective June 3, 2026).
Highlights of the sitagliptin record
Sitagliptin (Januvia) · label of November 14, 2024
Used for
From the label: indicationsJANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. […]
On the market
- Earliest approval on file
- October 16, 2006
- Generic labelers
- 4 labelers
- Pharmacy cost
- $3.77 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Highlights of the dapagliflozin record
Dapagliflozin (Farxiga) · label of June 3, 2026
Used for
From the label: indicationsFARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. […]
On the market
- Earliest approval on file
- January 8, 2014
- Generic labelers
- 22 labelers
- Pharmacy cost
- $0.184 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Source: FDA drug labels via openFDA (Sitagliptin label of November 14, 2024, Dapagliflozin label of June 3, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do sitagliptin and dapagliflozin differ on the record?
In FDA's classes, sitagliptin is a dipeptidyl peptidase 4 inhibitor and dapagliflozin a sodium-glucose cotransporter 2 inhibitor.
How each works, in its label's words: Sitagliptin, “Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones.”; Dapagliflozin, “Dapagliflozin is an inhibitor of SGLT2.”
Half-life, in each label's words: Sitagliptin, “Following a single oral 100-mg dose to healthy volunteers, mean plasma AUC of sitagliptin was 8.52 μM•hr, C max was 950 …”; Dapagliflozin, “The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of …”
Generics: sitagliptin since 2025; dapagliflozin since 2026 (Drugs@FDA).
| Sitagliptin | Dapagliflozin | |
|---|---|---|
| Labeled for | Type 2 diabetes | Chronic kidney disease, Heart failure, Type 2 diabetes |
| Pharmacologic class | Dipeptidyl Peptidase 4 Inhibitor | Sodium-Glucose Cotransporter 2 Inhibitor |
| How it works (label) | Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones. | Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. |
| Half-life (label) | Following a single oral 100-mg dose to healthy volunteers, mean plasma AUC of sitagliptin was 8.52 μM•hr, C max was 950 nM, and apparent terminal half-life (t 1/2 ) was 12.4 hours. | The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of FARXIGA 10 mg. |
| Earliest approval on file (Drugs@FDA) | October 16, 2006 | January 8, 2014 |
| First generic approved | December 29, 2025 | April 6, 2026 |
| Generic labelers (NDC) | 4 labelers | 22 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $3.77 per tablet (Sitagliptin phosphate 100 mg tablet) | $0.184 per tablet (Dapagliflozin 10 mg tablet) |
| 12-month price change | n/a | -98% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 1 | 0 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 74,197 | 56,884 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
Do their labels mention each other?
Dapagliflozin label, drug interactionsCoadministered Drug (Dose Regimen) Single dose unless otherwise noted.: Sitagliptin (100 mg); Dapagliflozin (Dose Regimen): 20 mg; Effect on Dapagliflozin Exposure [% Change (90% CI)]: ↔; ↔
Source: FDA drug labels via openFDA
What next?
- Alternatives to sitagliptin
- every medicine labeled for the same conditions